ASH 2020: Focus on CLL, MCL, and WM
In younger patients with mantle cell lymphoma (MCL), pre-transplant MRD status in both bone marrow and peripheral blood ...
Treatment with zanubrutinib was well tolerated and associated with high clinical activity in patients with ...
A novel idiotype (scFv-CCL20) DNA vaccine was associated with favorable perturbation of the immune microenvironment in ...
A study has found that the addition of rituximab to ixazomib, when used as maintenance therapy following autologous ...
A first-line regimen consisting of once-daily ibrutinib plus venetoclax was associated with high rates of undetectable ...
Early initiation of Bruton’s tyrosine kinase inhibitor zanubrutinib in patients with chronic lymphocytic leukemia ...
Venetoclax (Ven) has helped patients with chronic lymphocytic leukemia (CLL) achieve improved long-term outcomes with ...
A fixed-duration venetoclax (Ven)-based regimen is considered a standard of care (SOC) option for patients with ...
The introduction of novel agents has given patients with chronic lymphocytic leukemia (CLL) and small lymphocytic ...
The introduction of novel agents has changed the treatment landscape for chronic lymphocytic leukemia (CLL), but these ...
The prognosis for high-risk (HR) chronic lymphocytic leukemia (CLL) is poor. Clinical data have found that small ...
Patients with cancer may experience financial burden due to medical expenses, job disruption/loss, and other factors. ...
The use of NSC12, a novel small molecule that specifically halts the FGF/FGFR axis in Waldenstrom macroglobulinemia ...
Patients with chronic lymphocytic leukemia (CLL) who have mild residual lymphadenopathy are more likely to have a ...
A combination regimen consisting of duvelisib and venetoclax was well tolerated, clinically active, and led to ...
Highly selective and irreversible Bruton’s tyrosine kinase inhibitor orelabrutinib was associated with continuous ...
Parsaclisib was clinically active in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) who were ...
A study presented at the 62nd ASH Annual Meeting & Exposition evaluated the risk of cardiovascular (CV) adverse ...
The prognosis for patients with chronic lymphocytic leukemia (CLL) has seen recent improvements, but these benefits ...
Patients with chronic lymphocytic leukemia (CLL) may have an increased risk of atrial fibrillation (AF); among the risk ...
Patients with chronic lymphocytic leukemia (CLL) are at risk for secondary malignancies. However, this risk has not been ...
A study that was presented at the 62nd ASH Annual Meeting & Exposition evaluated real-world outcomes in patients ...
Patients with Waldenstrom macroglobulinemia (WM) who present with characteristics suggestive of a concomitant ...
Since 2006, clinicians treating Waldenstrom macroglobulinemia (WM) have shifted away from using chlorambucil as ...
Final results from the Nordic Lymphoma Group’s phase II PHILEMON trial showed that a combination of ibrutinib, ...
Venetoclax, Lenalidomide, and Rituximab Combo Is Well Tolerated, Shows Promising Efficacy in R/R MCL
A combination treatment approach consisting of venetoclax, lenalidomide, and rituximab was well tolerated and ...In older adult Medicare beneficiaries with CLL, treatment with ibrutinib was associated with a nearly threefold ...
The Chronic Lymphocytic Leukemia (CLL) Comorbidity Index (CLL-CI), which examines endocrine, vascular, and ...
Once-daily ibrutinib and rituximab (IR) was superior to placebo and rituximab in terms of prolonging progression-free ...
In the randomized, phase III MURANO study, patients with relapsed/refractory chronic lymphocytic leukemia (CLL) treated ...
Chemoimmunotherapy (CIT) is a common treatment option for patients with chronic lymphocytic leukemia (CLL) but may ...
Most patients diagnosed with chronic lymphocytic leukemia (CLL) are older; the median age at diagnosis is 70 years. Less ...
Zanubrutinib has been shown to be an effective treatment in patients with chronic lymphocytic leukemia (CLL)/small ...
Certain genomic abnormalities are predictive of poor outcomes in chemoimmunotherapy (CIT) in patients with chronic ...
Once-daily ibrutinib and rituximab (IR) was superior to placebo and rituximab in terms of prolonging progression-free ...
First-line treatment with bortezomib (B) plus dexamethasone, rituximab, and cyclophosphamide (DRC) was well tolerated ...
KTE-X19, an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, was associated with relatively high ...
A chemotherapy-free combination regimen consisting of ibrutinib and rituximab (IR) produced high response rates and ...
Treatment with umbralisib plus ublituximab was associated with significant improvements in progression-free survival ...
In treatment-naïve patients with chronic lymphocytic leukemia (CLL) and those with relapsed/refractory (R/R) CLL, ...
For patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), genetic risk factors may ...
Among patients with chronic lymphocytic leukemia (CLL) who receive chemoimmunotherapy, those with a partial response ...
Venetoclax has been shown to be effective in patients with relapsed/refractory chronic lymphocytic leukemia (CLL), ...
Acalabrutinib is approved for chronic lymphocytic leukemia (CLL), and although patients with CLL have presented durable ...
Advertisement
Advertisement
